Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010–2017

Diabetes, Obesity and Metabolism

Volumn 21, Issue 7, 2019, Pages 1576-1584

  Dennis, John M ^a   Henley, William E ^a   McGovern, Andrew P ^b   Farmer, Andrew J ^c   Sattar, Naveed ^d   Holman, Rury R ^c   Pearson, Ewan R ^e   Hattersley, Andrew T ^b   Shields, Beverley M ^b   Jones, Angus G ^b  

^a UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^b ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

glycaemic control; hypoglycaemia; primary care; SGLT2 inhibitor; type 2 diabetes; weight control

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; METFORMIN; PRESCRIPTION DRUG; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; BODY WEIGHT LOSS; CLINICAL OUTCOME; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION RESEARCH; PRESCRIPTION; PRIMARY MEDICAL CARE; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY ANALYSIS; SYSTOLIC BLOOD PRESSURE; TREND STUDY; UNITED KINGDOM; CLINICAL PRACTICE; DRUG EFFECT; GLUCOSE BLOOD LEVEL;

BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; PRACTICE PATTERNS, PHYSICIANS'; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 85063859359     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13687     Document Type: Article

References (39)

1. National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. NICE guideline (NG28). https://www.nice.org.uk/guidance/NG28. Published 2015. Accessed May 15, 2018.
2. American Diabetes Association. 8. Pharmacologic Approaches to Glycemic Treatment. Diabetes Care. 2017;40(Suppl 1):S64-S74.
3. Qaseem A, Barry MJ, Humphrey LL, Forciea MA. Clinical guidelines Committee of the American College of Physicians. Oral Pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline update from the American College of Physicians. Ann Intern Med. 2017;166(4):279-290.
4. Davies MJ, D'Alessio DA, Fradkin J, et al. Management of Hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Diabetes Care. 2018;41(12):2669-2701.
5. Montvida O, Shaw J, Atherton JJ, Stringer F, Paul SK. Long-term trends in antidiabetes drug usage in the U.S.: real-world evidence in patients newly diagnosed with type 2 diabetes. Diabetes Care. 2018;41(1):69-78.
6. Curtis HJ, Dennis JM, Shields BM, et al. Time trends and geographical variation in prescribing of drugs for diabetes in England from 1998 to 2017. Diabetes Obes Metab. 2018;20(9):2159-2168.
7. Wilkinson S, Douglas I, Stirnadel-Farrant H, et al. Changing use of antidiabetic drugs in the UK: trends in prescribing 2000-2017. BMJ Open. 2018;8(7):e022768.
8. Persson F, Bodegard J, Lahtela JT, et al. Different patterns of second-line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): a multinational observational study. Endocrinol Diabetes Metab. 2018;1(4):e00036.
9. Palmer SC, Mavridis D, Nicolucci A, et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA. 2016;316(3):313-324.
10. Wilding J, Godec T, Khunti K, et al. Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom clinical practice research datalink. BMC Med. 2018;16(1):116.
11. Heald AH, Livingston M, Malipatil N, et al. Improving type 2 diabetes mellitus glycaemic outcomes is possible without spending more on medication: lessons from the UKNational Diabetes Audit. Diabetes Obes Metab. 2018;20(1):185-194.
12. Lipska KJ, Yao X, Herrin J, et al. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006–2013. Diabetes Care. 2017;40(4):468-475.
13. Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: clinical practice research datalink (CPRD). Int J Epidemiol. 2015;44(3):827-836.
14. Clinical Practice Research Datalink. Clinical Practice Research Datalink Bibliography. https://www.cprd.com/Bibliography/. Accessed May 15, 2018.
15. Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press. http://www.medicinescomplete.com. Accessed May 15, 2018.
16. Rodgers LR, Weedon MN, Henley WE, Hattersley AT, Shields BM. Cohort profile for the MASTERMIND study: using the clinical practice research datalink (CPRD) to investigate stratification of response to treatment in patients with type 2 diabetes. BMJ Open. 2017;7(10):e017989.
17. Seidu S, Davies MJ, Mostafa S, deLusignan S, Khunti K. Prevalence and characteristics in coding, classification and diagnosis of diabetes in primary care. Postgrad Med J. 2014;90(1059):13-17.
18. Farmer R, Mathur R, Bhaskaran K, Eastwood SV, Chaturvedi N, Smeeth L. Promises and pitfalls of electronic health record analysis. Diabetologia. 2018;61(6):1241-1248.
19. Khunti K, Davies M, Majeed A, Thorsted BL, Wolden ML, Paul SK. Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study. Diabetes Care. 2015;38(2):316-322.
20. Williams R. Using the margins command to estimate and interpret adjusted predictions and marginal effects. Stata J. 2012;12(2):308-331.
21. Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet. 2012;380(9840):475-483.
22. Cefalu WT, Leiter LA, Yoon K-H, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382(9896):941-950.
23. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427-2443.
24. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.
25. Mazidi M, Rezaie P, Gao HK, Kengne AP. Effect of sodium-glucose Cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients. J Am Heart Assoc. 2017;6(6): pii):e004007.
26. Sun F, Wu S, Guo S, et al. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Res Clin Pract. 2015;110(1):26-37.
27. Zhang X, Zhao Q. Effects of dipeptidyl peptidase-4 inhibitors on blood pressure in patients with type 2 diabetes: a systematic review and meta-analysis. J Hypertension. 2016;34(2):167-175.
28. Zhong VW, Juhaeri J, Cole SR, et al. Incidence and trends in hypoglycemia hospitalization in adults with type 1 and type 2 diabetes in England, 1998–2013: a retrospective cohort study. Diabetes Care. 2017;40(12):1651-1660.
29. Read SH, Kerssens JJ, McAllister DA, et al. Trends in type 2 diabetes incidence and mortality in Scotland between 2004 and 2013. Diabetologia. 2016;59(10):2106-2113.
30. Zghebi SS, Steinke DT, Carr MJ, Rutter MK, Emsley RA, Ashcroft DM. Examining trends in type 2 diabetes incidence, prevalence and mortality in the UK between 2004 and 2014. Diabetes Obes Metab. 2017;19(11):1537-1545.
31. NHS Digital. Prescribing for Diabetes, England - 2006/07 to 2016/17. http://digital.nhs.uk/catalogue/PUB30043. Published August 1, 2017. Accessed May 15, 2018.
32. vanDalem J, Brouwers MC, Stehouwer CD, et al. Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study. BMJ. 2016;354:i3625.
33. Khunti K, Godec TR, Medina J, et al. Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second-line therapy after metformin monotherapy: retrospective data for 10 256 individuals from the United Kingdom and Germany. Diabetes Obes Metab. 2018;20(2):389-399.
34. Farmer AJ, Brockbank KJ, Keech ML, England EJ, Deakin CD. Incidence and costs of severe hypoglycaemia requiring attendance by the emergency medical services in south Central England. Diabet Med. 2012;29(11):1447-1450.
35. Dennis JM, Shields BM, Hill AV, et al. Precision medicine in type 2 diabetes: clinical markers of insulin resistance are associated with altered short- and long-term glycemic response to DPP-4 inhibitor therapy. Diabetes Care. 2018;41(4):705-712.
36. Dennis JM, Henley WE, Weedon MN, et al. Sex and BMI Alter the benefits and risks of sulfonylureas and Thiazolidinediones in type 2 diabetes: a framework for evaluating stratification using routine clinical and individual trial data. Diabetes Care. 2018;41(9):1844-1853.
37. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-322.
38. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644-657.
39. Zheng SL, Roddick AJ, Aghar-Jaffar R, et al. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis. JAMA. 2018;319(15):1580-1591.